Findings

What do systematic reviews say?

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Low

Intervention not reported

Polyneuropathies · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
82 participants
GRADE not reported

Intervention not reported

Quality of life · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Estimated treatment effect measured as Z‐scores*** after adjustment for the number of patients

1 finding from 1 review

Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intervention not reported

Frequency of statistically favourable results

It is very uncertain whether the intervention changes frequency of statistically favourable results (very low certainty).

1 finding from 1 review

Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological… 2019 · Cochrane Headline outcomes only
RR 0.84 [0.62, 1.14]
Studies not reported
Very low

Intervention not reported

Frequency of favourable conclusions

The intervention may leads to higher frequency of favourable conclusions (low certainty).

1 finding from 1 review

Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological… 2019 · Cochrane Headline outcomes only
RR 1.98 [1.26, 3.11]
Studies not reported
Low

Intervention not reported

Adults and adolescents · adults and children with chronic asthma

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Asthma‐related non‐fatal SAEc · adults and children with chronic asthma

The intervention showed no clear difference in asthma‐related non‐fatal SAEc (moderate certainty).

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
OR 1.25 [0.72, 2.16]
8 studies · 8453 participants
Moderate

Intervention not reported

All‐cause mortality · adults and children with chronic asthma

The intervention showed no clear difference in all‐cause mortality (moderate certainty).

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
OR 0.8 [0.36, 1.78]
41 studies · 27951 participants
Moderate

Intervention not reported

All‐cause non‐fatal SAEc · adults and children with chronic asthma

The intervention showed no clear difference in all‐cause non‐fatal SAEc (moderate certainty).

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
OR 1.14 [0.97, 1.33]
41 studies · 27951 participants
Moderate

Intervention not reported

Asthma‐related mortality · adults and children with chronic asthma

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
no estimate extracted
41 studies · 27951 participants
Moderate

Intervention not reported

Asthma‐related non‐fatal SAEc · adults and children with chronic asthma

The intervention showed no clear difference in asthma‐related non‐fatal SAEc (low certainty).

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
OR 1.15 [0.83, 1.59]
41 studies · 27951 participants
Low

Intervention not reported

Children · adults and children with chronic asthma

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · adults and children with chronic asthma

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 8453 participants
Moderate

Intervention not reported

All‐cause non‐fatal SAEc · adults and children with chronic asthma

The intervention showed no clear difference in all‐cause non‐fatal SAEc (moderate certainty).

1 finding from 1 review

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events 2018 · Cochrane Headline outcomes only
OR 1.04 [0.73, 1.48]
8 studies · 8453 participants
Moderate